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Photodynamic therapy (PDT) involves a two-stage process. A light-absorbing photosensitiser (Ps) is endocytosed and then stimulated
by light, inducing transfer of energy to a cytoplasmic acceptor molecule and the generation of reactive oxygen species that initiate
damage to cellular membrane components and cytolysis. The expanded use of PDT in the clinic is hindered by the lack of Ps target-
cell specificity and the limited tissue penetration by external light radiation. This study demonstrates that bioconjugates composed of
transferrin and haematoporphyrin (Tf–Hp), significantly improve the specificity and efficiency of PDT for erythroleukemic cells by a
factor of almost seven-fold. Fluorescence microscopy showed that the conjugates accumulate in intracellular vesicles whereas free Hp
was mostly membrane bound. Experiments with cells deliberately exposed to Tf–Hp at oLD100 doses showed that surviving cells
did not develop resistance to subsequent treatments with the conjugate. Furthermore, we show that the compound luminol induces
intracellular chemiluminescence. This strategy was then used to obviate the use of external radiation for Ps activation by incubating
the cells with luminol either before or together with Tf–Hp. This novel chemical means of PDT activation induced cytotoxicity in
95% of cells. These combined approaches provide an opportunity to develop broader and more effective applications of PDT.
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The nonselectivity of chemotherapeutic agents has stimulated
development of targeted drug delivery strategies such as ligand
toxin conjugates (LTCs), involving the coupling of an effector
molecule to a transport ligand of a target cell-specific receptor
(Rihova, 1998; Mrsny, 2004). Smaller ligands such as peptides or
other small molecules may have advantages over larger molecules
like antibodies (Rihova, 1998; Shadidi and Sioud, 2003). We
recently reported on the use of small molecule-containing LTCs
for the targeted destruction of plasma cells (Firer et al, 2003)
suggesting that this approach may be applicable for multiple
myeloma therapy. The LTC strategy for targeting tumour cells
represents one focus of the present study.
The second focus involves photodynamic therapy (PDT), a two-
stage procedure based on two nontoxic components that combine
to induce membrane alterations leading to cytolysis. The first
component is a photosensitiser (Ps) molecule, usually a porphyrin
derivative, that when light-activated transfers energy to molecular
oxygen, producing reactive oxygen species that cause direct
damage to cellular components, particularly membrane phospho-
lipids. Photodynamic therapy is believed to mediate tumour cell
destruction by at least two additional mechanisms: destruction
of tumour vascular cells and the induction of both inflammatory
and immune antitumour reactions (Dougherty et al, 1998; van
Duijnhoven et al, 2003). The history, mechanism of action and
biomedical applications of PDT have been the subject of several
comprehensive reviews (Ceburkov and Gollnick, 2000; Dolmans
et al, 2003; Brown et al, 2004; Sharman et al, 2004).
Two major issues limit the wider application of PDT as a
treatment modality. First, whereas Pss tend to accumulate in
tumour tissue, their clinical use is often associated with side
effects such as cutaneous photosensitivity (Vrouenraets et al, 2003;
Sharman et al, 2004). To overcome this problem investigators have
covalently linked the Ps to carrier molecules so as to localise the
PDT effect (Klyashchitsky et al, 1994; Vrouenraets et al, 2003). One
attractive carrier protein–receptor system for this purpose utilises
the high-affinity interaction between the iron-transporter trans-
ferrin (Tf) and its cell-surface receptor (TfR, CD71). As all dividing
cells require a continuous supply of iron for metabolism, it is not
surprising that TfR is overexpressed on a variety of malignant cells
(Ponka et al, 1998), so the Tf–TfR system has been used in several
formats to target Ps compounds to different types of malignant
cells (Hamblin and Newman, 1994; Rittenhouse-Diakun et al, 1995;
Cavanaugh, 2002; Gijsens et al, 2002; Li and Qian, 2002). The
second major issue regarding PDT is the limited tissue penetration
of external laser light. Despite advances in the development of
external light devices for phototherapy (Brancaleon and Moseley,
2002) and the successful clinical use of PDT for peripheral cancers
(Stockfleth and Sterry, 2002; Dolmans et al, 2003; Moan and Peng,
2003; Brown et al, 2004) and in dermatology (Ceburkov and
Gollnick, 2000), the treatment of internal body tissues remains
limited to invasive procedures, such as the use of endoscopes.
Although these procedures may involve acceptable discomfort to
the patient compared to other treatments such as surgery, there are
only isolated reports of attempts to develop molecular approaches
to Ps activation. These studies used chemiluminescence (CL), in Revised 5 June 2006; accepted 6 June 2006; published online 4 July 2006
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swhich the in situ conversion of molecular oxygen to superoxide
ions and the subsequent release of light energy achieved is with-
out electrical input or thermal output. Carpenter et al (1994)
employed intracellular bioluminescent activation of hypericin
and the subsequent destruction of equine dermal cells, whereas
Phillip and Maximuke (1989) used a haematoporphyrin derivative
(Photofrin II) and a multicomponent solution to induce intra-
cellular CL in mammary adenocarcinomas. In searching for a
simple means to induce intracellular CL, we turned to luminol,
which has been successfully used in a variety of CL-based assays
systems (Kricka, 2002). The mechanism of the CL reaction of
luminol has been known for some time (White et al, 1964) and
whereas some physico-chemical aspects of luminol activation in
macrophages have been examined (Nemeth et al, 1999), the
luminol–PDT connection has never been exploited to induce PDT
cytotoxicity in tumour cells.
The present study combines these new approaches to overcome
the above-mentioned limitations to PDT applications. We first
demonstrate the efficacy of the targeted LTC strategy using the
transferrin and haematoporphyrin (Tf–Hp) system. We then
establish in vitro proof of principle that luminol can be used as a
powerful molecular inducer of intracellular CL for the destruction
of leukemic cells, overcoming the need of external light sources
in PDT.
MATERIALS AND METHODS
Hp, rabbit anti-human transferrin, goat anti-bovine serum
albumin (BSA), transferrin, N-hydroxysuccinimide and luminol
(5-amino-2-3-dihydro-1, 4-phtalazinedione) were purchased from
Sigma-Aldrich Chemical Co., Rehovot, Israel, N,N-dicyclohexyl
carbodiimide (DCC) and tetrahydrofuran were from Carlo Erba,
Radona, Italy. Horse serum (HS), fetal calf serum, Dulbecco’s
modified Eagle’s medium (DMEM), RPMI, L-glutamine and
combined antibiotics were purchased from Biological Industries
Ltd (Bet Haemek, Israel). High-pressure liquid chromatography
(HPLC) solvents were from Merck, Rosh Haayin, Israel.
Cells
U7.6 is a murine hybridoma that secretes IgG1 antibody against
dinitrophenol and was a kind gift of Professor Eshhar (Weizmann
Institute of Science, Rehovot, Israel). These cells as well as Friend’s
leukaemia (FL) cells were grown in DMEM containing 15% HS,
2m ML -glutamine and combined antibiotics. Human K-562 cells
were grown in RPMI/15% HS/glutamine/antibiotics. All cells were
maintained at 371C in a humidified incubator containing 6% CO2
and were passaged every 3–4 days. For the experiments described
here, cells were grown from a single frozen vial of each cell type.
Preparation of Hp containing LTCs
Haematoporphyrin hydrochloride (0.11mmol) was dissolved in
10ml chloroform and activated by addition of 0.173mmol of
N-hydroxysuccinimide and 0.11mmol DCC. The mixture was
stirred at room temperature for 2.5h. Following evaporation with a
stream of air, the residue was dissolved in 2ml of tetrahydrofuran
(THF) and the activated Hp was slowly added to a solution of
15mg transferrin dissolved in 10ml of 0.1 M NaHCO3 cooled on
ice. The solution was allowed to warm to room temperature,
adjusted to pH 7.5 and stirred vigorously overnight. Tubes
containing Hp were protected from light exposure. The conjugate
solution was centrifuged (7200g, 30min, 41C) and the supernatant
was analysed spectroscopically for the content of protein
(l¼280nm) and Hp (l¼400nm). After dialysis, a small portion
of the crude reaction product was chromatographed over Sephadex
G-50 equilibrated with 5mM NaHCO3 (pH 8.0) or 10mM
phosphate-buffered saline (PBS) (pH 7.2). Fractions containing
materials with absorption peaks at 280 and 400nm were collected
and stored at 41C.
Characterisation of the Tf–Hp conjugate
High-pressure liquid chromatography Tf, Hp and Tf–Hp were
chromatographed over a C-18 column (3.9 300mm Bondclone,
particle diameter 10mm, Phenomenex, Torrance, CA, USA) using
a HPLC JASCO-1580 with a JASCO 1575 UV/VIS detector set at
280nm. The solvent system was composed of acetonitrile–water
with 1% trifluoroacetic acid and compounds were eluted with a
linear gradient (20–100% acetonitrile).
Absorbance spectrum The absorbance spectra of PBS solutions of
Hp (0.02mgml
 1), Tf (1.4mgml
 1) and Hp-Tf (1.4mgml
 1) were
recorded with a CHEMUSB2-UV-VIS spectrophotometer having
optical resolution of 1nm, grating of 600 linesmm
 1 equipped
with CCD array detector. The samples were scanned in the
absorbance region of 250–500nm.
Biological activity This was assessed by the ability of antitrans-
ferrin or anti-BSA antibodies to inhibit PDT-induced cytotoxicity.
Friend’s leukaemia cells were cultured with 3mM Tf–Hp in the
LTC cytotoxicity assay (see below) together with 0–200mgml
 1 of
each antibody.
Ligand toxin conjugate cytotoxicity assay
Late log-phase cells were washed with DMEM prewarmed to 371C
and cultured at 0.5–1 10
5cellsml
 1 either alone or with
increasing concentrations of Tf–Hp LTC for 2h at 371Ci n6 %
CO2. Cells were then washed with DMEM, exposed to white
fluorescent light (fluence rate¼0.5mWcm
 2) overnight, usually
16h and then recultured in full medium for 24h. The emission
spectrum covered the wavelengths 350–700nm. Cell viability
was determined by trypan blue exclusion. Experiments were
repeated at least three times. The optimal exposure times of cells to
the Ps and fluorescent radiation were determined in preliminary
time-course experiments (data not shown).
Fluorescence microscopy of Hp and Tf–Hp endocytosis
Friend’s leukaemia cells were grown on glass slides in tissue
culture dishes together with Hp or Tf–Hp and the incorporated
fluorescence was followed at various time intervals with an AX70
Olympus microscope equipped with a high-pressure mercury lamp
for excitation and a set of filters for blue violet excitation (band
path 420–480nm), dichroic mirror (455nm) and a cut-on red
emission barrier filter (580nm). Fluorescence was analysed with an
60  objective, without addition of any antibleaching solution, and
recorded by a CCD camera.
Cellular uptake of Tf–Hp conjugate
To ascertain the kinetics of cellular uptake of the Tf–Hp conjugate,
10
6ml
 1 FL cells were incubated at 371C for 0, 15, 30, 60 or 120min
with 3mgml
 1 Tf–Hp. The cells were then washed three times with
PBS and the fluorescence was measured by FACSCalibur (Beckon
Dickinson, San Jose, CA, USA). Approximately 10
4 cells were
analysed in each sample. From the output data, the increase in
mean fluorescence units per minute was calculated.
Resistance to Tf–Hp treatment
To test the effect of repeated exposure to Tf–Hp, FL cells
were treated with Tf–Hp in the cytotoxicity assay as described
above. Cells surviving treatment at the LD90 concentration were
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smaintained in Tf–Hp-free culture medium until they regained
pretreatment growth kinetics (approximately 3 weeks). These cells
were designated ‘Single treatment FL.’ and together with previously
untreated FL, were tested for their response to a range of LTC
doses. Single-treatment FL cells surviving a second exposure at
LD90 were in turn cultured and termed ‘Double treatment FL.’ This
cycle was repeated to derive ‘Triple treatment FL.’
Measurement of intracellular CL induced by luminol
To ascertain the ability of luminol to induce intracellular
luminescence, we performed measurements using a fluorescence
spectrometer (Varian Eclipse, Palo Alto, CA, USA) set at bio/CL
mode. Stock solutions of 100mM luminol in 10% NaOH and 5mM
ferrous sulphate and LB buffer (0.14 M NaCl, 0.027 M KCl, 0.012 M
Na2HPO4.2H2O, 0.015 M K2PO4, 0.9mM CaCl2, 0.5mM MgCl2.6H20,
pH¼7.6, Kawagoe and Nakagawa, 2000) were prepared. A mixture
of 1mM luminol, 1mM iron catalyst and 1% H2O2 was also pre-
pared and used to calibrate the system. Then to measure the
influence of luminol on cellular luminescence, log-phase FL cells
were collected, washed twice in LB buffer, resuspended at 10
5
or 10
6 viable cellsml
 1 in LB bufferþ1m M iron catalyst alone or
together with 1mM luminol. The cell suspensions were monitored
for CL for up 50min.
Intracellular PDT activation by luminol
In initial experiments, FL cells were washed and cultured for 20h
with different concentrations of Hp or Tf–Hp (0.07, 0.15 or 0.3mM)
together with luminol (0–10mM). All manipulations of cells and
components were performed with the room lights switched off.
Culture plates were wrapped in aluminium foil during the culture
period. Subsequent experiments aimed to test whether a PDT effect
could be obtained by staggering the exposure of the cells to either
luminol or Tf–Hp conjugate. In one series, FL cells were cultured
for 2h in the dark at 371C with Tf–Hp (3mM), washed and
resuspended in medium at the standard culture concentration.
This procedure took approximately 15min. Then, the cells were
kept at 371C for an additional 0, 30, 60 or 90min, luminol (10mM)
was added and the cultures incubated in the dark for a further 16h.
Alternatively, cells were first cultured for 24h in the dark in the
presence of 10mM luminol, washed or not-washed and then
cultured further for 24h in the presence of Tf–Hp (0–3mM)a t
371C. During washing procedures and cell handling, special care
was taken to maintain the cells in a dark environment.
Statistical analysis
Statistical analyses of the data were performed by two-way
analysis of variance (ANOVA) (F-distribution) and least-squares
regression.
RESULTS
Purification and characterisation of the Tf–Hp conjugate
The Tf–Hp conjugate was separated from Tf and Hp by HPLC and
characterised by UV-Vis spectrophotometry (Figure 1). The Tf
spectrum reveals a typical maximum at l¼280nm, whereas Hp
absorption maximum is at l¼375nm. The Hp–Tf conjugate
revealed two absorption peaks at l¼280 and 412nm and the
spectrum is characterised by a red shift of the maximum and is not
a simple superposition of the spectra of its components. The molar
ratio of the two conjugates components was determined spectro-
scopically to be 6.3 Hp/1 Tf. The biological activity of the conjugate
was verified by determining the ability of antibodies to interfere
with LTC cytotoxicity. The addition of antitransferrin to assay
cultures of FL cells reduced cytotoxicity by 50% at 100mgml
 1
antibody and by 95% at 200mgml
 1 antibody. The addition of
anti-BSA to parallel cultures reduced cytotoxicity by 10 and 5%,
respectively.
Direct cytotoxicity of Tf–Hp LTCs with external
photoactivation
Friend’s leukaemia, K562 and U-76 cells were incubated with
various concentrations of Hp or Tf–Hp in the dark for 2h and then
exposed overnight exposure to white fluorescent light. Control cells
kept under similar environmental conditions but not exposed to Hp
or light showed 95% viability. Treatment with high concentrations
of Tf–Hp alone induced low-level cytotoxicity (Figure 7). For all cell
types, dose–response effect (Figure 2) of Tf–Hp was significantly
more cytotoxic than Hp alone (for FL P¼0.042; for K-562 P¼0.034,
for U-76 P¼0.038). Table 1 shows that the concentration of Tf–Hp
required to achieve LD50 was more than six-fold lower than for Hp.
Furthermore LD100 values were only obtained with the Tf–Hp. U-76
hybridoma cells were relatively insensitive to PDT. The concentra-
tion of Tf–Hp required to reach LD90 in these cells was 419.4-fold
higher than for FL cells and 43.5-fold higher than for K-562 cells.
This order of sensitivity was retained at the concentrations required
for LDMAX (3.37 for FL and 0.8 for K562). Furthermore, 100%
cytotoxicity was only obtained when the conjugate was used against
the erythroleukemic cell lines. A similar pattern of sensitivity was
also seen with free Hp treatment. Although a similar (90%) LDMAX
was reached for both erythroleukemic lines, FL cells were 16.6 more
sensitive than K-562.
Further evidence for the increased cytotoxicity of Tf–Hp over
free Hp was obtained from fluorescence microscopy. Figure 3
illustrates the presence and location of the Ps in FL cells after 45
and 60min incubation with either Hp (left panel) or Tf–Hp (right
panel). At both time points, relatively faint (as no anti bleaching
solution was used) Hp fluorescence was observed mainly
constrained to the plasma membrane region. Significantly greater
fluorescence was apparent in cells treated with Tf–Hp. After
45min, the conjugate localised in membrane patches (probably
demarcating endolysosomal compartments) and had infiltrated
much of the cytoplasm by 60min.
The characteristics of Tf–Hp uptake kinetics in the FL were
examined by incubating them with conjugate for various times and
measuring the cell-associated fluorescence by fluorescence-acti-
vated cell sorting (FACS). Figure 4 shows that the uptake was
linear over the 120min of the experiments with an uptake rate of
0.056 arbitrary fluorescence unitsmin
 1.
Resistance of FL cells to repeated Tf–Hp treatments
We tested whether repeated exposure to Tf–Hp may lead to the
development of resistance in treated cells by adapting a protocol
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Figure 1 UV-VIS absorbance spectra in the interval of 250–500nm for
Hp (------), Tf ( ) and Hp-Tf ( ) prepared in PBS (for concentrations
see Materials and Methods).
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sused previously by us to study resistance to a ligand–Ricin A
conjugate (Firer et al, 2003). Figure 5 shows the dose–response
curve of FL cells exposed to a range of Tf–Hp concentrations (first
treatment). Those surviving the LD90 dose were passaged over
several weeks in Tf–Hp-free medium and then retested for their
dose–response to Tf–Hp (second treatment). This process was
repeated (third treatment). This protocol of repeated exposure
did not result in the development of resistant cells as would be
demonstrated by a shift to the right in the dose–response curve.
Indeed, statistical analysis by ANOVA at different Tf–Hp
concentrations showed that repeated treatment of FL cells
resulted in a statistically significant elevation in PDT sensitivity
at 0.75mgml
 1 Tf–Hp (Po0.009) and at 1.5mgml
 1 Tf–Hp
(Po0.012). At 3mgml
 1 Tf–Hp, there was no significant
difference between the first, second or third treatments.
Intracellular CL by luminol
Experiments were performed to determine whether luminol is
capable of inducing intracellular CL. Friend’s leukaemia cells
were incubated with a source of catalyst (ferrous sulphate) with
or without luminol and CL measurements were made using a
fluorescence spectrometer. Figure 6 shows that incubation of cells
with catalyst did produce notable CL over a 50min incubation
period. However, addition of luminol to the cell suspension
resulted in measurable luminescence after about 20min incubation
that peaked after an additional 10min.
Intracellular PDT activation of Hp or Tf–Hp by luminol
Despite the effective action of the Tf–Hp, PDT for leukemia would
be limited in vivo by the restricted tissue penetration of candescent
light. We therefore tested the possibility of generating an
intracellular chemiluminescent light signal to induce PDT. Figure 7
illustrates the cytotoxicity induced in FL cells cultured in the dark
with Hp or Tf–Hp either alone or together with 10mM luminol as
the chemiluminescent energy source. The cells were not exposed to
ambient fluorescent light at any stage of the procedure. We found
Concentration of Hp alone or in Hp-Tf (M)
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Figure 2 Dose-dependent cytotoxicity of Hp and Tf–Hp for cells FL
(A), K562 (B) and U-7.6 (C) cells. 0.5–1 10
5cellsml
 1 were cultured
for 2h in the dark in medium alone or containing Hp or Tf–Hp (0–3mM),
washed, exposed to ambient fluorescent light for 16h at room
temperature and then recultured in full medium for 24h. Cell viability
was assessed by trypan blue exclusion. The data represent the mean and
standard deviation from at least three experiments.
Table 1 Comparison of cytotoxic efficiency of PDT induced by Tf–Hp
or Hp for three cell lines
Cell type
Parameter FL K-562 U-7.6
Concentration at LD50 (mM)
Hp 0.55 1.9 NR
Tf–Hp 0.08 0.3 0.5
Ratio
a 6.88 6.33 —
Concentration at LD90 (mM)
Hp NR 7.5 NR
Tf–Hp 0.18 1.0 43.5
Ratio
a — 7.5 —
Concentration at LDMAX (mM)
Hp 0.89 7.5 3.0
Tf–Hp 0.45 3.75 3.0
Ratio
a 1.98 2.0 1.0
% Cell cytotoxicity at LDMAX
Hp 84 90 40
Tf–Hp 100 100 85
Ratio
a 0.84 0.90 0.47
aRatio of Hp/Tf-Hp. NR¼not reached.
Hematoporphyrin Transferrin-
hematoporphyrin
45 min
60 min
Figure 3 Fluorescent microscopy of Hp and Tf–Hp-treated FL cells.
Cells were grown on glass slides in tissue culture dishes together with
medium containing 1mM of Hp or Tf–Hp for 45 and 60min and then
examined for fluorescence emission. Hp was found in relatively low levels
around the cytoplasmic membrane whereas Tf–Hp was mainly internalised
in intracellular vesicles.
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sthat (i) luminol alone induced about 15% cytotoxicity, (ii) Hp
alone had little effect on cell viability, (iii) cytotoxicity reached a
maximum of 30% in the presence of Hp and luminol and (iv)
luminol induced a significant PDT effect upon addition of Tf–Hp
(P¼0.0043). Figure 8 further demonstrates that the cytotoxic
luminol-induced PDT effect is dependent on the concentration of
both Tf–Hp and luminol with a combination of 10mM luminol and
3mM of conjugate producing maximum cytotoxicity. A reduction
in Tf–Hp concentration had less effect on cytotoxicity than did
diluting the level of luminol. We tested if synchrony in exposure
to luminol and Tf–Hp is a requirement for this cytotoxicity by
incubating cells first with Tf–Hp, washing and then exposing them
to luminol following various delay times. The time taken to wash
the cells and return them to culture was approximately 15min.
Although delaying the exposure to luminol by 30min had no effect
on the cytotoxicity (Figure 9A), after 60min of delay, the PDT
effect was reduced by 50%. However by reversing the protocol
(Figure 9B), we found that preincubation with luminol for 24h
sensitised the cells to the delayed exposure to Tf–Hp and the PDT
effect was dose dependent. Washing or not washing the luminol-
incubated cells before their exposure to Tf–Hp had no significant
effect on the IAP activity.
DISCUSSION
This study addresses two aspects of PDT technology. The first
concerns the development of PDT systems to enhance the
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Figure 4 Kinetics of Tf–Hp uptake into FL cells. 106 cells were
incubated with 3mg Tf–Hp for the times indicated. Cells were washed
three times with PBS and fluorescence measured by FACS. The figure
depicts the increase in the mean arbitrary fluorescence units measured for
the total cell sample measured (approx. 103 cells at each time period) vs
incubation time. The least-squares linear regression line also shown.
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Figure 5 Repeated exposure to Tf–Hp does not induce resistance in
treated cells. Friend’s leukaemia cells were treated with Tf–Hp for dose–
response (see Materials and Methods) (B). Cells surviving treatment at the
LD90 concentration were cultured in Tf–Hp-free culture medium for
approximately 3 weeks and then re-tested, together with fresh FL cells, for
their dose–response to Tf–Hp challenge (’). Cells surviving this second
treatment at the LD90 were processed through a third treatment cycle
( ). Cell viability was determined by trypan blue exclusion. Data points
represent the mean7standard deviation of three experiments. Photo-
dynamic therapy sensitivity of FL cells was significantly increased after
repeated exposure to Tf–Hp at 0.75mgml
 1 Tf–Hp (Po0.009) and at
1.5mgml
 1 Tf–Hp (Po0.012).
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Figure 6 Intracellular CL in FL cells induced by luminol. Cells were
suspended in LB buffer (see Materials and Methods)þ1m M iron catalyst
and used to measure background CL (graph A) over a 50min incubation
period. A separate aliquot of cells were similarly suspended but together
with 1mM luminol (graph B). Measurements were made with a
fluorescence spectrometer set to bio/CL mode and the readout was in
arbitrary units.
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Figure 7 Molecular, intracellular activation of the PDT effect. FL cells
were cultured in the dark for 48h at 371C with haematoporphyrin (Hp) or
Tf–Hp conjugate (0–3mM) together with 10mM luminol. No other
manipulation or external radiation of the cells was performed. At the end
of the culture period, cell viability was determined by trypan blue exclusion.
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sefficiency of delivery to target cells. Most (Hamblin and Newman,
1994; Klyashchitsky et al, 1994; Dolmans et al, 2003), but not all
(Gijsens et al, 2002; Sharman et al, 2004) targeted PDT studies have
used monoclonal antibodies as the address moiety. As the use of
antibodies poses several practical limitations (Rihova, 1998), an
alternate approach is to target a Tf–Ps conjugate to Tf receptors
that are overexpressed on tumour cells (Faulk et al, 1980;
Cavanaugh, 2002). The therapeutic potential of Tf–protein
(Weaver and Laske, 2003) and Tf–chemical (Singh et al, 1998)
toxin conjugates have already been examined, but less is known
about Tf–Ps conjugates particularly with regard to Hp which,
although having been used successfully in free form in the clinic
for over a decade (Dolmans et al, 2003; Brown et al, 2004), has
been little tested in targeted PDT (Hamblin and Newman, 1994;
Gijsens et al, 2002).
We prepared and characterised Tf–Hp conjugates and found
that these were at least six-fold more effective in inducing cell
death at the LD50 level (Figure 2 and Table 1). High concentrations
of Tf–Hp alone induced low-level cytotoxicity in accordance with
previous reports (Supino et al, 1986; Luksiene and de Witte, 2003),
an effect that may be related to the ability of Hp to inhibit the
activity of protein kinase C (Luksiene and de Witte, 2003).
However, there was variability among the cells in their sensitivity
to PDT, with erythroleukemic cells showing between 3.5 and
19.4-fold greater sensitivity than hybridoma cells. We have seen
a similar relative lack of PDT sensitivity in other hybridoma
cells (data not shown) and, although we did not measure this
parameter, we believe that it reflects the high TfR levels on
erythroid cells. A similar pattern of sensitivity was also seen with
free Hp treatment. Because in order to induce cytotoxicity Hp
must interact with cell membrane lipids (Ehrenberg et al, 1985),
the results suggest that the molecular makeup of the three cell
membranes is different. This assumption is supported by earlier
studies showing that variation in lipid bilayer components, in
particular cholesterol and phosphatidylcholine, influences the
binding and depth of penetration of Hp into cell membranes and
liposomes (Lavi et al, 2002). Consideration should also be made as
to the relative contributions of Tf and Hp to the overall contact
between the conjugate and the cell membrane. We do not know
the spatial orientation of the two components within the conjugate
but the observation that in FL cells for example, a three-fold
increase in cytotoxicity was obtained with Tf–Hp as compared
to free Hp, suggests that the Tf makes a foremost contribution
to the conjugate–membrane interaction and/or the effectiveness
of its uptake.
Aside from increasing target specificity and efficiency, PDT-
induced cell death is faster when Tf–Hp is used. For example,
during optimisation of the LTC cytotoxicity assay we noticed that
whereas almost 100% cytotoxicity was achieved after only 30min
exposure to Tf–Hp, about 2h were required for maximum activity
(24%) of free Hp (data not shown). Moreover, fluorescence
microscopy of Hp and Tf–Hp-treated FL cells (Figure 3) demon-
strated that Tf–Hp is taken up more rapidly and that it reaches
intracellular organelles and this would provide for more effective
disruption of intracellular membranes. This is relevant in light of
data demonstrating that
1O2 molecules generated by Ps activation
rapidly diffuse out of the cell surface bilayer (Lavi et al, 2002).
An important limitation of current chemotherapy is the frequent
induction of multidrug resistance (MDR) in treated cells to a range
of compounds that share apparently no structural or functional
similarities (Hirose, 2002; Liscovitch and Lavie, 2002). Several
cell surface transporter proteins have been identified as central
components in this phenomenon (Gottesman et al, 2002).
Interestingly, we (Firer et al, 2003) and others (Wang et al, 2000;
Mazel et al, 2001) have shown that LTCs comprising protein toxins
or DNA-damaging drugs seem to bypass the MDR transporters
and do not to induce resistance. This is probably due to the
pathway of cell entry that involves receptor-mediated endocytosis,
initial passage of the LTC to lysosomes and then release of
the toxin component to other intracellular targets, such as the
endoplasmic reticulum and nucleus. With regards to PDT, whereas
this modality has been found effective against MDR tumour cells
(Capella and Capella, 2003; Preise et al, 2003), very few studies
have directly approached the possibility of resistance developing
to repeated Ps exposure. Madsen et al (2003) for instance reported
that no resistance developed in glioma spheroids repeatedly
exposed to free 5-aminoelulinic acid but as we have shown that
LTCs are much more effective than free Ps we subjected FL cells to
several rounds of treatment with suboptimal doses of Tf–Hp
(Figure 5). Our results support Madsen et al’s conclusion that PDT
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Figure 8 The effect of component concentration of the IAP. Friend’s
leukaemia cells were cultured in the dark for 48h at 371C with varying
concentration combinations of Tf–Hp conjugate (0–3mM) and luminol
(0–10mM). No other manipulation or external radiation of the cells was
performed. At the end of the culture period, cell viability was determined
by trypan blue exclusion.
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371C with Tf–Hp (3mM) and washed. After various delay times (0, 30, 60
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further 16h in the dark. The figure shows the % of induced cytotoxicity.
The 0 delay point includes time for washing of cells and returning them to
the culture (approximately 15min). (B) Effect of pretreatment of FL cells
by luminol on cell growth inhibition by Tf–Hp. The cells were first cultured
for 24h in the presence of 10mM luminol in the dark for 24h, washed or
nonwashed and then cultured for a further 24h in the presence of Tf–Hp
(0–3mM)a t3 7 1C.
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well recognised resistance that FL cells develop to repeated
exposure to other cytotoxins such as anthracyclines (Abbadessa
et al, 1992; Desoize et al, 1994). From the fluorescence microscopy
results (Figure 3), it may be postulated that LTC treatment
concentrates the Ps in intracellular organelles that are not available
to MDR transporters. The data from Figure 5 further indicate that
FL cells surviving an initial LTC-PDT attack become more
sensitive to subsequent treatments. At this point, we do not have
an explanation for this phenomenon.
The second issue of PDT technology we addressed concerned the
source of the luminescent activating signal delivered to the Ps.
External radiation provides homogeneous excitation of Ps to cells in
tissue culture or those injected subcutaneously; however, penetration
of visible spectrum light waves into internal tissue is not uniform
for all wavelengths (Moan and Peng, 2003) as after only a few
millimeters, the cellular mass causes a dramatic drop in and
scattering of transferred energy, precluding the use of PDT for
deeper tissue targets (Ceburkov and Gollnick, 2000). Efforts to
overcome this limitation have concentrated on new external light
devices (Brancaleon and Moseley, 2002; Chen et al,2 0 0 2 )o r
improved catheters. Our aim was to provide a molecular light-
emitting mechanism within or at least proximal to the Ps-loaded
target cell. This strategy is noninvasive, does not expose normal
tissue to irradiation and a molecular illuminator could potentially be
transported to any target cell in vivo.W eu s et h et e r mintracellular
activation of PDT (IAP) to describe such molecular systems.
One CL activator is luminol, which undergoes a light-emitting
process catalysed by metal ions and hydrogen peroxide (White
et al, 1964; Weeks, 1992). This process is extensively employed in
chemiluminescent detection techniques (Kricka, 2002; Templin
et al, 2002) and in cell physiology studies (Kubo et al, 1987;
Nemeth et al, 1999; Kawagae and Nakagawa, 2000) but there is no
literature on the use of luminol as an energy source in the field of
PDT of cancer cells. The emission spectrum of luminol has been
reported to comprise two major peaks, at 424 and 485nm (White
et al, 1964). We found that the first of these corresponds to a crest
in the absorption spectrum of Tf–Hp (412nm) but not to those
of free Hp or Tf (375 and 280nm, respectively, Figure 1). This
information, together with the enhanced intracellular uptake of the
Tf–Hp relative to Hp suggested to us that an IAP involving
luminol might be effective for our system.
Firstly, we determined that luminol could indeed induce
intracellular CL. Figure 6 demonstrates that after a period of
incubation, cells exposed in the dark to luminol and an iron
catalyst luminescence. This response was not of rapid onset that
might reflect slow cellular uptake of luminol. In subsequent
experiments, Hp or Tf–Hp was mixed with luminol and added to
FL cell culture in the dark (Figure 7). Not only was there a
significant PDT effect when both Tf–Hp and luminol were added
to the cells, but the cytotoxic efficiency of Tf–Hp over Hp was even
more enhanced than that seen with the external light source
(Figure 2). However, the concentration of Tf–Hp required to attain
LDMAX in the IAP system was 6.7 times higher than with external
radiation (Figure 7 and Table 1). Luminol alone appeared to
induce little cytotoxicity and these levels were similar to the PBS
control (data not included in the figure). As this IAP system
progresses to in vivo studies one important parameter to test will
be the physiological effect, in any, of luminol. Little information
is currently available on this issue, although a recent study by
Sanders et al (2000) demonstrated that the compound had no
detrimental effect on rat metabolism.
Luminol-induced CL has been used in the past to study
physiological parameters of phagocytic cells, as these produce the
H2O2 needed for luminol oxidation (Nemeth et al, 1999; Dunn et al,
2005). But nonphagocytic cells, such as those used in this study, also
possess several potential pathways through which to generate
luminol-activating H2O2. These include a variety of signalling path-
ways (Finkel, 1998) and intracellular iron metabolism (Caltagirone
et al, 2001). Also, reactive oxygen species such as O2* produced in
mitochondria by the electron transport chain are dismuted to H2O2
(Batandier et al, 2002), which diffuses into the cytoplasm (Antunes
and Cadenas, 2000). Oxidant products of nitric oxide have also been
shown to activate luminal (Catz et al, 1995).
Other IAP systems have also been studied. Carpenter et al (1994)
described a bioluminescent mechanism for PDT that induced
killing of virus-infected cells, involving the activation of hypericin
following oxidation of luciferin by luciferase. They too reported
that a continuous source of external radiation resulted in more
effective target cell cytotoxicity and suggested that this may be
related to suboptimal proximity between the luciferin and the
hypericin. An alternate explanation based on the short half-life of
the CL reaction itself (B1min) and rapid decrease in light
emission intensity cannot be ruled out. Whatever the explanation,
these limitations might be overcome by incorporating enhancer
molecules into the IAP system to prolong and intensify the
luminescent signal analogous to improvements made to the
original chemiluminescent techniques (Kricka, 2000).
Additional experiments (Figure 9) demonstrated that the Ps and
IAP systems need not be applied simultaneously in order to
produce an effective PDT response. Delaying the addition of
luminol (by up to 45min) to Tf–Hp-loaded cells, or delaying the
addition of Tf–Hp (24h) to luminol-loaded cells did not affect
cytotoxicity. As the loaded cells were thoroughly washed before the
exposure to luminol, these results reflect activation of the
internalised Tf–Hp or luminol rather than material loosely bound
to the membrane.
In conclusion, our data demonstrate that Tf–Hp conjugates
represent an effective vehicle for PDT-induced cytotoxicity.
Transferrin conjugates are being clinically tested against neurolo-
gical tumours (Hall, 2000) and it remains to be seen whether the
presence of Tf receptors on normal cells will preclude the use of
Tf–Hp against haematological cancers (Hamblin and Newman, 1994;
Brown et al, 2004). Experience with monoclonal antibodies against
nontumour-specific antigens such as CD20 and EGFR (Tobinai,
2002; Goldberg, 2005) suggests that the enhanced expression of
TfR on tumour cells and the targeting effect of Tf–Hp may provide
an effective therapeutic window. We are currently studying this
with in vivo murine models. Finally, the ability to activate the PDT
effect intracellularly without the need for external radiation opens
the way for wider application of PDT technology, particularly
where internal diseased tissues are the target.
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